Page 41 - Read Online

Peixoto et al. Cancer Drug Resist 2018;1:219-29 I http://dx.doi.org/10.20517/cdr.2018.17 Page 229

34. Zhang Y, Xiang C, Wang Y, Duan Y, Liu C, et al. PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in
NSCLC patients with EGFR-TKI resistance. Oncotarget 2017;8:101535-44.
35. Goltz D, Gevensleben H, Vogt TJ, Dietrich J, Golletz C, et al. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4
immunotherapy in melanoma patients. JCI Insight 2018; doi: 10.1172/jci.insight.96793.
36. Goltz D, Gevensleben H, Dietrich J, Ellinger J, Landsberg J, et al. Promoter methylation of the immune checkpoint receptor PD-1
(PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical
prostatectomy. Oncoimmunology 2016;5:e1221555.
37. Goltz D, Gevensleben H, Grünen S, Dietrich J, Kristiansen G, et al. PD-L1 (CD274) promoter methylation predicts survival in patients
with acute myeloid leukemia. Leukemia 2017;31:738-43.
38. Wu J, Xu X, Lee EJ, Shull AY, Pei L, et al. Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with
epigenetic reprogramming. Oncotarget 2016;7:40558-70.
39. Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, et al. PD-L1 expression is regulated by both DNA methylation and NF-kB
during EMT signaling in non-small cell lung carcinoma. Oncoimmunology 2018;7:e1423170.
40. Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med 2016;213:2835-40.
41. Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, et al. De novo epigenetic programs inhibit pd-1 blockade-mediated t cell
rejuvenation. Cell 201;170:142-57.
42. Ørskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, et al. Hypomethylation and up-regulation of PD-1 in T cells by
azacytidine in MDS/AML patients: a rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 2015;6:9612-26.
43. Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, et al. Epigenetic prediction of response to
anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respir Med 2018;6:771-81.
44. Rieke DT, Ochsenreither S, Klinghammer K, Seiwert TY, Klauschen F, et al. Methylation of RAD51B, XRCC3 and other homologous
recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma
of the head and neck, lung and cervix. Oncotarget 2016;7:75379-93.
45. Franzen A, Vogt TJ, Müller T, Dietrich J, Schröck A, et al. PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is
associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. Oncotarget 2018;9:641-50.
46. Goltz D, Gevensleben H, Dietrich J, Schroeck F, de Vos L, et al. PDCD1 (PD-1) promoter methylation predicts outcome in head and
neck squamous cell carcinoma patients. Oncotarget 2017;8:41011-20.
47. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in
myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014;28:1280-8.
48. Lai Q, Wang H, Li A, Xu Y, Tang L, et al. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-
L1 signal of lung cancer cells. Oncogene 2018;37:2302-12.
49. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by
suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014;111:11774-9.
50. Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, et al. HDAC inhibition potentiates immunotherapy in triple negative
breast cancer. Oncotarget 2017;8:114156-72.
51. Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, et al. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen
presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol Immunother
2018;67:381-92.
52. Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med
2007;204:1543-51.
53. Mu L, Long Y, Yang C, Jin L, Tao H, et al. The IDH1 mutation-induced oncometabolite, 2-hydroxyglutarate, may affect DNA
methylation and expression of PD-L1 in gliomas. Front Mol Neurosci 2018;11:82.
54. Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Neuro Oncol 2017;19:1460-8.
55. Lee KS, Lee K, Yun S, Moon S, Park Y, et al. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. J
Neurooncol 2018;136:453-61.
56. Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Clin Epigenetics 2017;9:59.
57. Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and
enhances antitumor efficacy of immune checkpoint blockade. Oncogene 2018; doi: 10.1038/s41388-018-0451-5.
58. Lu C, Paschall AV, Shi H, Savage N, Waller JL, et al. The MLL1-H3K4me3 Axis-mediated PD-L1 expression and pancreatic cancer
immune evasion. J Natl Cancer Inst 2017; doi: 10.1093/jnci/djw283.
59. Arenas-Ramirez N, Sahin D, Boyman O. Epigenetic mechanisms of tumor resistance to immunotherapy. Cell Mol Life Sci
2018;75:4163-76.
60. Cartron PF, Blanquart C, Hervouet E, Gregoire M, Vallette FM. HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-
UHRF1-G9a regulate the NY-ESO1 gene expression. Mol Oncol 2013;7:452-63.
61. Kroesen M, Büll C, Gielen PR, Brok IC, Armandari I, et al. Anti-GD2 mAb and vorinostat synergize in the treatment of neuroblastoma.
Oncoimmunology 2016;5:e1164919.
62. Song KH, Choi CH, Lee HJ, Oh SJ, Woo SR, et al. HDAC1 upregulation by NANOG promotes multidrug resistance and a stem-like
phenotype in immune edited tumor cells. Cancer Res 2017;77:5039-53.
63. Wu L, Cao J, Cai WL, Lang SM, Horton JR, et al. KDM5 histone demethylases repress immune response via suppression of STING.
PLoS Biol 2018;16:e2006134.